Busca avançada
Ano de início
Entree
(Referência obtida automaticamente do Web of Science, por meio da informação sobre o financiamento pela FAPESP e o número do processo correspondente, incluída na publicação pelos autores.)

Activity of paromomycin against Leishmania amazonensis: Direct correlation between susceptibility in vitro and the treatment outcome in vivo

Texto completo
Autor(es):
Coser, Elizabeth M. [1] ; Ferreira, Bianca A. [1] ; Branco, Nilson [1] ; Yamashiro-Kanashiro, Edite H. [2, 3] ; Lindoso, Jose Angelo L. [4, 5] ; Coelho, Adriano C. [1]
Número total de Autores: 6
Afiliação do(s) autor(es):
[1] Univ Estadual Campinas, Inst Biol, Dept Biol Anim, UNICAMP, Campinas - Brazil
[2] Univ Sao Paulo, Fac Med, Inst Med Trop Sao Paulo, Lab Soroepidemiol & Imunobiol, Sao Paulo - Brazil
[3] Univ Sao Paulo, Fac Med, Dept Molestias Infecciosas & Parasitarias, Lab Imunol LIM 48, Sao Paulo - Brazil
[4] Inst Infectol Emilio Ribas, Sao Paulo - Brazil
[5] Univ Sao Paulo, Fac Med, Inst Med Trop Sao Paulo, Lab Protozool, Dept Molestias Infecciosas & Parasi, Sao Paulo - Brazil
Número total de Afiliações: 5
Tipo de documento: Artigo Científico
Fonte: INTERNATIONAL JOURNAL FOR PARASITOLOGY-DRUGS AND DRUG RESISTANCE; v. 14, p. 91-98, DEC 2020.
Citações Web of Science: 1
Resumo

Paromomycin is an aminoglycoside antibiotic approved in 2006 for the treatment of visceral leishmaniasis caused by Leishmania donovani in Southeast Asia. Although this drug is not approved for the treatment of visceral and cutaneous leishmaniasis in Brazil, it is urgent and necessary to evaluate the potential of this drug as alternative for the treatment against species responsible for these clinical forms of the disease. In Brazil, Leishmania amazonensis is responsible for cutaneous and diffuse cutaneous leishmaniasis. The diffuse cutaneous form of the disease is difficult to treat and frequent relapses are reported, mainly when the treatment is interrupted. Here, we evaluated paromomycin susceptibility in vitro of a L. amazonensis clinical isolate from a patient with cutaneous leishmaniasis and the reference strain L. amazonensis M2269, as well as its in vivo efficacy in a murine experimental model. Although never exposed to pammomycin, a significant differential susceptibility between these two lines was found. Paromomycin was highly active in vitro against the clinical isolate in both forms of the parasite, while its activity against the reference strain was less active. In vivo studies in mice infected with each one of these lines demonstrated that paromomycin reduces lesion size and parasite burden and a direct correlation between the susceptibility in vitro and the effectiveness of this drug in vivo was found. Our findings indicate that paromomycin efficacy in vivo is dependent on intrinsic susceptibility of the parasite. Beyond that, this study contributes for the evaluation of the potential use of paromomycin in chemotherapy of cutaneous leishmaniasis in Brazil caused by L. amazonensis. (AU)

Processo FAPESP: 16/21171-6 - Paromomicina no tratamento da Leishmaniose Tegumentar: investigação in vitro, in vivo e na identificação de marcadores moleculares associados à suscetibilidade e resistência
Beneficiário:Adriano Cappellazzo Coelho
Linha de fomento: Auxílio à Pesquisa - Apoio a Jovens Pesquisadores
Processo FAPESP: 18/03299-0 - Avaliação da eficácia da paromomicina no tratamento da leishmaniose tegumentar experimental
Beneficiário:Elizabeth Magiolo Coser
Linha de fomento: Bolsas no Brasil - Mestrado
Processo FAPESP: 20/01948-1 - Avaliação da suscetibilidade in vitro a fármacos alternativos em isolados clínicos e de cães de Leishmania spp
Beneficiário:Bianca Alves Ferreira
Linha de fomento: Bolsas no Brasil - Mestrado